Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Accounts Payables (2020 - 2025)

Maravai Lifesciences Holdings has reported Accounts Payables over the past 6 years, most recently at $2.9 million for Q4 2025.

  • Quarterly results put Accounts Payables at $2.9 million for Q4 2025, down 75.66% from a year ago — trailing twelve months through Dec 2025 was $2.9 million (down 75.66% YoY), and the annual figure for FY2025 was $2.9 million, down 75.66%.
  • Accounts Payables for Q4 2025 was $2.9 million at Maravai Lifesciences Holdings, down from $8.0 million in the prior quarter.
  • Over the last five years, Accounts Payables for MRVI hit a ceiling of $718.2 million in Q4 2022 and a floor of $2.9 million in Q4 2025.
  • Median Accounts Payables over the past 5 years was $9.7 million (2021), compared with a mean of $111.9 million.
  • Biggest five-year swings in Accounts Payables: surged 8707.95% in 2022 and later plummeted 98.96% in 2024.
  • Maravai Lifesciences Holdings' Accounts Payables stood at $8.2 million in 2021, then surged by 8707.95% to $718.2 million in 2022, then plummeted by 98.51% to $10.7 million in 2023, then grew by 11.45% to $12.0 million in 2024, then tumbled by 75.66% to $2.9 million in 2025.
  • The last three reported values for Accounts Payables were $2.9 million (Q4 2025), $8.0 million (Q3 2025), and $11.5 million (Q2 2025) per Business Quant data.